- Author: Brian Wong, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
Rapid cure of gonorrhea is critical to curtail transmission. Because of emerging resistance that has resulted in limited choices for antibiotics, it is imperative to follow treatment guidelines to avoid further resistance and to obtain optimal treatment results. For more information, see CDC Sexually Transmitted Diseases Treatment Guidelines, 2015.
Medical therapy requires dual antibiotic treatment with efficacy against N gonorrhoeae. Until several years ago, the treatment of choice involved oral medication for as long as 10 days or an injection; however, patients tend to be poorly compliant with medications for various reasons, and the availability of newer medications has allowed in-office single-doses of ceftriaxone IM plus azithromycin PO treatment to ensure compliance.
After obtaining specimens for diagnosis, many practitioners presumptively treat patients based on history and examination, because of the risk of poor follow-up, complications, and continuing disease spread to other partners. In addition, because gonorrhea is often simultaneously diagnosed with chlamydia , many practitioners treat patients for both diseases when treating for either one beyond the newborn period.
Disseminated or complicated infections (eg, endocarditis, meningitis) require more prolonged, inpatient therapy. For these cases, an infectious disease consultation is essential.
N gonorrhoeae in the United States is not adequately susceptible to penicillins, fluoroquinolones, or erythromycin for these antimicrobials to be recommended.
Ceftriaxone is part of the dual-drug regimen (along with azithromycin) for treating gonorrhea because of the attainment of high, sustained bactericidal levels in the blood. Ceftriaxone binds to penicillin-binding proteins, inhibiting bacterial cell wall growth.
Azithromycin inhibits bacterial growth, possibly by blocking the dissociation of peptidyl transfer ribonucleic acid (tRNA) from ribosomes, causing RNA-dependent protein synthesis to arrest. It is part of the first-line preferred dual-drug regimen for gonococcal infections plus ceftriaxone IM.
Cefixime, a cephalosporin, inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins. It is not used first-line and it is an alternant therapy for uncomplicated gonorrhea if ceftriaxone is unavailable. For this situation, patients can be given a single oral dose of cefixime 400 mg plus a single dose of azithromycin 1 g PO.
Doxycycline inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Doxycycline 100 mg PO BID for 10-14 days may be used in addition to a single dose of ceftriaxone 250 mg IM for gonococcal epididymitis or pelvic inflammatory disease.
Erythromycin is the only antibiotic ophthalmic ointment recommended for use in neonates for prophylaxis of gonococcal ophthalmia neonatorum. Silver nitrate and tetracycline ophthalmic ointments are no longer manufactured in the United States, bacitracin is not effective, and povidone iodine has not been studied adequately. Gentamicin ophthalmic ointment has been associated with severe ocular reactions in neonates and should not be used for ocular prophylaxis.
Dawe RS, Sweeney G, Munro CS. A vesico-pustular rash and arthralgia. Clin Exp Dermatol. 2001 Jan. 26(1):113-4. [Medline].
Belding ME, Carbone J. Gonococcemia associated with adult respiratory distress syndrome. Rev Infect Dis. 1991 Nov-Dec. 13(6):1105-7. [Medline].
Walters DG, Goldstein RA. Adult respiratory distress syndrome and gonococcemia. Chest. 1980 Mar. 77(3):434-6. [Medline].
Thiéry G, Tankovic J, Brun-Buisson C, Blot F. Gonococcemia associated with fatal septic shock. Clin Infect Dis. 2001 Mar 1. 32(5):E92-3. [Medline].
[Guideline] CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007 Apr 13. 56(14):332-6. [Medline].
Cucurull E, Espinoza LR. Gonococcal arthritis. Rheum Dis Clin North Am. 1998 May. 24(2):305-22. [Medline].
Watring WG, Vaughn DL. Gonococcemia in pregnancy. Obstet Gynecol. 1976 Oct. 48(4):428-30. [Medline].
Angulo JM, Espinoza LR. Gonococcal arthritis. Compr Ther. 1999 Mar. 25(3):155-62. [Medline].
Holder NA. Gonococcal infections. Pediatr Rev. 2008 Jul. 29(7):228-34. [Medline].
Ilina EN, Vereshchagin VA, Borovskaya AD, Malakhova MV, Sidorenko SV, Al-Khafaji NC, et al. Relation between genetic markers of drug resistance and susceptibility profile of clinical Neisseria gonorrhoeae strains. Antimicrob Agents Chemother. 2008 Jun. 52(6):2175-82. [Medline].
Palmer HM, Young H, Graham C, Dave J. Prediction of antibiotic resistance using Neisseria gonorrhoeae multi-antigen sequence typing. Sex Transm Infect. 2008 Aug. 84(4):280-4. [Medline].
Warner L, Stone KM, Macaluso M, Buehler JW, Austin HD. Condom use and risk of gonorrhea and Chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis. 2006 Jan. 33(1):36-51. [Medline].
Kerle KK, Mascola JR, Miller TA. Disseminated gonococcal infection. Am Fam Physician. 1992 Jan. 45(1):209-14. [Medline].
Little JW. Gonorrhea: update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Feb. 101(2):137-43. [Medline].
Centers for Disease Control and Prevention (CDC). 2010 Sexually Transmitted Diseases Surveillance: Gonorrhea. Available at http://www.cdc.gov/std/stats10/gonorrhea.htm. Accessed: May 21 2012.
National Institute of Allergy and Infectious Diseases. Gonorrhea. Available at http://www.niaid.nih.gov/topics/gonorrhea/Pages/default.aspx. Accessed: August 16, 2011.
Centers for Disease Control and Prevention. 2009 Sexually Transmitted Diseases Surveillance: Gonorrhea. Available at http://www.cdc.gov/STD/stats09/gonorrhea.htm. Accessed: 5/27/11.
Mulye TP, Park MJ, Nelson CD, Adams SH, Irwin CE Jr, Brindis CD. Trends in adolescent and young adult health in the United States. J Adolesc Health. 2009 Jul. 45(1):8-24. [Medline].
Bleich AT, Sheffield JS, Wendel GD Jr, Sigman A, Cunningham FG. Disseminated gonococcal infection in women. Obstet Gynecol. 2012 Mar. 119(3):597-602. [Medline].
Da Ros CT, Schmitt Cda S. Global epidemiology of sexually transmitted diseases. Asian J Androl. 2008 Jan. 10(1):110-4. [Medline].
AVERT.org. STD Statistics Worldwide. Available at http://www.avert.org/stdstatisticsworldwide.htm.
World Health Organization. Emergence of multi-drug resistantNeisseria gonorrhoeae –Threat of global rise in untreatable sexuallytransmitted infections. Available at http://whqlibdoc.who.int/hq/2011/WHO_RHR_11.14_eng.pdf. Accessed: August 16, 2011.
World Health Organization. Initiative for Vaccine Research (IVR). Available at http://www.who.int/vaccine_research/diseases/soa_std/en/index2.html. Accessed: August 16, 2011.
Goodyear-Smith F. What is the evidence for non-sexual transmission of gonorrhoea in children after the neonatal period? A systematic review. J Forensic Leg Med. 2007 Nov. 14(8):489-502. [Medline].
Martin IM, Foreman E, Hall V, Nesbitt A, Forster G, Ison CA. Non-cultural detection and molecular genotyping of Neisseria gonorrhoeae from a piece of clothing. J Med Microbiol. 2007 Apr. 56:487-90. [Medline].
Trent M, Haggerty CL, Jennings JM, Lee S, Bass DC, Ness R. Adverse adolescent reproductive health outcomes after pelvic inflammatory disease. Arch Pediatr Adolesc Med. 2011 Jan. 165(1):49-54. [Medline].
Stefanelli P. Emerging resistance in Neisseria meningitidis and Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2011 Feb. 9(2):237-44. [Medline].
García PJ, Holmes KK, Cárcamo CP, et al. Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet. 2012 Mar 24. 379(9821):1120-8. [Medline]. [Full Text].
Meyers D, Wolff T, Gregory K, et al. USPSTF recommendations for STI screening. Am Fam Physician. 2008 Mar 15. 77(6):819-24. [Medline].
Schachter J, Hook EW 3rd, McCormack WM, Quinn TC, Chernesky M, Chong S, et al. Ability of the digene hybrid capture II test to identify Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens. J Clin Microbiol. 1999 Nov. 37(11):3668-71. [Medline].
Verzijl A, Berretty PJ, Erceg A, Krekels GA, Van den Brule AJ, Boel CH. [A pseudo-outbreak of pharyngeal gonorrhoea related to a false-positive PCR-result]. Ned Tijdschr Geneeskd. 2007 Mar 24. 151(12):689-91. [Medline].
Wada K, Uehara S, Mitsuhata R, et al. Prevalence of pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae among heterosexual men in Japan. J Infect Chemother. 2012 Apr 11. [Medline].
Muralidhar B, Rumore PM, Steinman CR. Use of the polymerase chain reaction to study arthritis due to Neisseria gonorrhoeae. Arthritis Rheum. 1994 May. 37(5):710-7. [Medline].
Kimmitt PT, Kirby A, Perera N, et al. Identification of Neisseria gonorrhoeae as the causative agent in a case of culture-negative dermatitis-arthritis syndrome using real-time PCR. J Travel Med. 2008 Sep-Oct. 15(5):369-71. [Medline].
Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Melby KK, Moi H, et al. Clinical validation of a real-time polymerase chain reaction detection of Neisseria gonorrheae porA pseudogene versus culture techniques. Sex Transm Dis. 2008 May. 35(5):517-20. [Medline].
Whiley DM, Garland SM, Harnett G, Lum G, Smith DW, Tabrizi SN, et al. Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health. 2008 Mar. 5(1):17-23. [Medline].
McNally LP, Templeton DJ, Jin F, Grulich AE, Donovan B, Whiley DM, et al. Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis. 2008 Jul 15. 47(2):e25-7. [Medline].
Alary M, Gbenafa-Agossa C, Aïna G, Ndour M, Labbé AC, Fortin D, et al. Evaluation of a rapid point-of-care test for the detection of gonococcal infection among female sex workers in Benin. Sex Transm Infect. 2006 Dec. 82 Suppl 5:v29-32. [Medline].
Greer L, Wendel GD Jr. Rapid diagnostic methods in sexually transmitted infections. Infect Dis Clin North Am. 2008 Dec. 22(4):601-17, v. [Medline].
Unemo M, Shipitsyna E, Domeika M. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sex Transm Infect. 2010 Nov. 86(6):442-4. [Medline].
Centers for Disease Control and Prevention. Cephalosporin Susceptibility Among Neisseria gonorrhoeae Isolates --- United States, 2000--2010. MMWR Morb Mortal Wkly Rep. 2011 Jul 8. 60(26):873-7. [Medline].
Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. MMWR Morb Mortal Wkly Rep. 2012 Aug 10. 61:590-4. [Medline]. [Full Text].
Brown T. Multidrug-Resistant Gonorrhea: New Treatment Guidelines. Available at http://www.medscape.com/viewarticle/779587. Accessed: February 27, 2013.
Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis. 2009 May 1. 48(9):1237-43. [Medline].
Melville NA. Two new antibiotics show efficacy in gonorrhea treatment. Medscape Medical News. July 16, 2013. [Full Text].
Kirkcaldy R. Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomised trial of new potential treatment options [abstract]. Sex Transm Infect. 89:A14-A15. [Full Text].
The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP). Two New Promising Treatment Regimens for Gonorrhea. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/nchhstp/newsroom/2013/Gonorrhea-Treatment-Trial-PressRelease.html. Accessed: July 16, 2013.
Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998 Feb 15. 57(4):735-46. [Medline].
American Academy of Ophthalmology Cornea/External Disease Panel. Conjunctivitis. National Guideline Clearinghouse. 2008.
Van Howe RS. Genital ulcerative disease and sexually transmitted urethritis and circumcision: a meta-analysis. Int J STD AIDS. 2007 Dec. 18(12):799-809. [Medline].
Owusu-Edusei K Jr, Bohm MK, Chesson HW, Kent CK. Chlamydia screening and pelvic inflammatory disease: Insights from exploratory time-series analyses. Am J Prev Med. 2010 Jun. 38(6):652-7. [Medline].
Lin JS, Whitlock E, O'Connor E, Bauer V. Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Oct 7. 149(7):497-508, W96-9. [Medline].
Barclay L. ACOG recommends expedited partner therapy for STIs. Medscape Medical News. WebMD Inc. Available at http://www.medscape.com/viewarticle/845221. May 22, 2015;
[Guideline] American College of Obstetricians and Gynecologists. Committee opinion no 632: expedited partner therapy in the management of gonorrhea and chlamydial infection. Obstet Gynecol. 2015 Jun. 125 (6):1526-8. [Medline].
Fletcher PS, Shattock RJ. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr Opin Investig Drugs. 2008 Feb. 9(2):189-200. [Medline].
CDC, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010, Dec 17. 59(RR-12):1-110. [Full Text].
Centers for Disease Control and Prevention. Neisseria gonorrhoeae with reduced susceptibility to azithromycin--San Diego County, California, 2009. MMWR Morb Mortal Wkly Rep. 2011 May 13. 60(18):579-81. [Medline].
Department of Health and Human Services. Azithromycin resistance in Hawaii (May 24, 2011). Available at http://www.cdc.gov/std/gonorrhea/DCL-Azithro-GC-May-24-2011.pdf. Accessed: August 16, 2011.
Kirkcaldy RD, Ballard RC, Dowell D. Gonococcal resistance: are cephalosporins next?. Curr Infect Dis Rep. 2011 Apr. 13(2):196-204. [Medline].
Kunz AN, Begum AA, Wu H, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis. 2012 Jun. 205(12):1821-9. [Medline].
Availability of cefixime 400 mg tablets--United States, April 2008. MMWR Morb Mortal Wkly Rep. 2008 Apr 25. 57(16):435. [Medline].
Ackerman AB. Hemorrhagic bullae in gonococcemia. N Engl J Med. 1970 Apr 2. 282(14):793-4. [Medline].
Allen VG, Mitterni L, Seah C, Rebbapragada A, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013 Jan 9. 309(2):163-70. [Medline].
Azariah S, Perkins N. Risk factors and characteristics of patients with gonorrhoea presenting to Auckland Sexual Health Service, New Zealand. N Z Med J. 2007 Apr 13. 120(1252):U2491. [Medline].
CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007 Apr 13. 56(14):332-6. [Medline]. [Full Text].
Centers for Disease Control and Prevention (CDC). Increases in gonorrhea--eight western states, 2000--2005. MMWR Morb Mortal Wkly Rep. 2007 Mar 16. 56(10):222-5. [Medline].
Chacko MR, Wiemann CM, Kozinetz CA, et al. New sexual partners and readiness to seek screening for chlamydia and gonorrhoea: predictors among minority young women. Sex Transm Infect. 2006 Feb. 82(1):75-9. [Medline]. [Full Text].
Chen PL, Hsieh YH, Lee HC, et al. Suboptimal therapy and clinical management of gonorrhoea in an area with high-level antimicrobial resistance. Int J STD AIDS. 2009 Apr. 20(4):225-8. [Medline].
Department of Health and Human Services, Centers for Disease Control and Prevention. STD Surveillance 2006: Trends in Reportable Sexually Transmitted Diseases in the United States, National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis. Available at http://www.cdc.gov/std/stats/trends2006.htm.
Driessen CM, de Jong SA, Bastiaens MT, Hissink Muller W, Weenink JJ, Spooren PF. [Dermatitis or arthritis as a sign of gonorrhoea]. Ned Tijdschr Geneeskd. 2011. 155:A2250. [Medline].
Gonococcal Isolate Surveillance Project (GISP) Annual Report 2005. Sexually Transmitted Disease Surveillance 2005 Supplement. CDC. January 2007. [Full Text].
Harth W, Linse R. Dermatological symptoms and sexual abuse: a review and case reports. J Eur Acad Dermatol Venereol. 2000 Nov. 14(6):489-94. [Medline].
Laidman J. Gonorrhea Resistant to Cefixime Found in North America. Medscape Medical News. Jan 8, 2013. Available at http://www.medscape.com/viewarticle/777287. Accessed: February 12, 2013.
Walters N, Butani L. A 16-year-old girl with recent disseminated gonococcemia now presenting with a facial rash. Ann Allergy Asthma Immunol. 2005 Feb. 94(2):224-7. [Medline].